{"nctId":"NCT00614939","briefTitle":"Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment","startDateStruct":{"date":"2008-01"},"conditions":["Type 2 Diabetes"],"count":572,"armGroups":[{"label":"Saxa","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin"]},{"label":"Placebo","type":"NO_INTERVENTION","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Saxagliptin","otherNames":["Onglyza"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes\n* Documented history of CrCl \\<50 ml/min within the 3 months prior to enrollment\n* HbA1c ≥7.0% and ≤11.0%\n\nExclusion Criteria:\n\n* Type 1 diabetes, history of diabetic ketoacidosis or hyposmolar non-ketonic coma\n* Previous or current treatment with any DPP-IV inhibitor and/or GLP-1 mimetic.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 12 Last Observation Carried Forward (LOCF)","description":"Adjusted\\* mean change from baseline in HbA1c achieved with saxagliptin 2.5 mg once daily versus placebo at Week 12 (Full Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated at the Week 12 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.09","spread":"0.119"},{"groupId":"OG001","value":"8.45","spread":"0.135"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.80","spread":"0.137"},{"groupId":"OG001","value":"7.63","spread":"0.132"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.109"},{"groupId":"OG001","value":"-0.86","spread":"0.112"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF)- Moderate Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 12 (Full Analysis Set) for the moderate renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 12 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.33","spread":"8.933"},{"groupId":"OG001","value":"202.82","spread":"9.858"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174.50","spread":"10.089"},{"groupId":"OG001","value":"173.91","spread":"7.938"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.88","spread":"9.073"},{"groupId":"OG001","value":"-15.22","spread":"8.630"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF) - Severe Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 12 (Full Analysis Set) for the severe renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 12 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173.48","spread":"11.630"},{"groupId":"OG001","value":"165.50","spread":"19.909"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141.52","spread":"14.276"},{"groupId":"OG001","value":"133.83","spread":"11.371"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.91","spread":"11.212"},{"groupId":"OG001","value":"-34.28","spread":"12.677"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF) - End-Stage Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 12 (Full Analysis Set) for the end-stage renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 12 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170.39","spread":"14.518"},{"groupId":"OG001","value":"177.07","spread":"10.638"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161.11","spread":"12.624"},{"groupId":"OG001","value":"207.60","spread":"30.515"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.18","spread":"20.752"},{"groupId":"OG001","value":"32.82","spread":"22.737"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF) - Moderate Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 12 (Full Analysis Set) for the moderate renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 12 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.01","spread":"0.495"},{"groupId":"OG001","value":"11.25","spread":"0.548"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.68","spread":"0.560"},{"groupId":"OG001","value":"9.65","spread":"0.441"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.504"},{"groupId":"OG001","value":"-0.84","spread":"0.479"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF) - Severe Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 12 (Full Analysis Set) for the severe renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 12 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.63","spread":"0.646"},{"groupId":"OG001","value":"9.17","spread":"1.105"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.86","spread":"0.793"},{"groupId":"OG001","value":"7.43","spread":"0.632"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.66","spread":"0.623"},{"groupId":"OG001","value":"-1.89","spread":"0.704"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF) - End-Stage Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 12 (Full Analysis Set) for the end-stage renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 12 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.46","spread":"0.807"},{"groupId":"OG001","value":"9.83","spread":"0.591"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.94","spread":"0.700"},{"groupId":"OG001","value":"11.52","spread":"1.692"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.62","spread":"1.151"},{"groupId":"OG001","value":"1.81","spread":"1.261"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 52","description":"Adjusted\\* mean change from baseline in HbA1c achieved with saxagliptin 2.5 mg once daily versus placebo at Week 52 (Full Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated at the Week 52 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.10","spread":"0.120"},{"groupId":"OG001","value":"8.44","spread":"0.134"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.93","spread":"0.173"},{"groupId":"OG001","value":"7.41","spread":"0.138"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.154"},{"groupId":"OG001","value":"-1.35","spread":"0.174"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - Moderate Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 52 (Full Analysis Set) for the moderate renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 52 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.33","spread":"8.933"},{"groupId":"OG001","value":"202.82","spread":"9.858"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174.83","spread":"11.295"},{"groupId":"OG001","value":"177.43","spread":"7.637"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":"13.277"},{"groupId":"OG001","value":"-14.96","spread":"12.873"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - Severe Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 52 (Full Analysis Set) for the severe renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 52 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173.48","spread":"11.630"},{"groupId":"OG001","value":"165.50","spread":"19.909"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151.78","spread":"9.896"},{"groupId":"OG001","value":"139.06","spread":"12.408"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.59","spread":"14.510"},{"groupId":"OG001","value":"-40.32","spread":"20.789"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - End-Stage Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 52 (Full Analysis Set) for the end-stage renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 52 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170.39","spread":"14.518"},{"groupId":"OG001","value":"177.07","spread":"10.638"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161.94","spread":"13.097"},{"groupId":"OG001","value":"214.27","spread":"31.740"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.18","spread":"29.226"},{"groupId":"OG001","value":"-40.28","spread":"45.470"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - Moderate Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 52 (Full Analysis Set) for the moderate renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 52 value minus the baseline value","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.01","spread":"0.495"},{"groupId":"OG001","value":"11.25","spread":"0.548"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.70","spread":"0.627"},{"groupId":"OG001","value":"9.85","spread":"0.424"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.738"},{"groupId":"OG001","value":"-0.82","spread":"0.715"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - Severe Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 52 (Full Analysis Set) for the severe renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 52 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.63","spread":"0.646"},{"groupId":"OG001","value":"9.17","spread":"1.105"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.42","spread":"0.551"},{"groupId":"OG001","value":"7.71","spread":"0.688"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.37","spread":"0.805"},{"groupId":"OG001","value":"-2.25","spread":"1.154"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - End-Stage Renal Impairment Subgroup","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 2.5 mg once daily versus placebo at Week 52 (Full Analysis Set) for the end-stage renal impairment subgroup. FPG is a continuous measure, the change from baseline for each participant is calculated at the Week 52 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.46","spread":"0.807"},{"groupId":"OG001","value":"9.83","spread":"0.591"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.99","spread":"0.728"},{"groupId":"OG001","value":"11.89","spread":"1.760"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"1.621"},{"groupId":"OG001","value":"-2.25","spread":"2.522"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":85},"commonTop":["Hypoglycaemia","Anaemia","Hypertension","Oedema Peripheral","Urinary Tract Infection"]}}}